COLLEGIUM PHARMACEUTICAL INC (COLL)
Health Care · Specialty pain management and ADHD pharmaceuticals · NASDAQ
A specialty pharma company building a diversified pain and ADHD portfolio through branded products and acquisitions, though facing material generic headwinds on its opioid franchise.
What COLLEGIUM PHARMACEUTICAL INC does
Collegium Pharmaceutical is a diversified biopharmaceutical company that develops, licenses, and commercializes branded prescription medicines for ADHD and moderate to severe pain management. The company's portfolio includes Jornay PM (evening-dosed ADHD stimulant), Belbuca (buprenorphine-based pain treatment), Xtampza ER (abuse-deterrent oxycodone), the Nucynta products (tapentadol formulations for pain), and Symproic (opioid-induced constipation treatment), all marketed in the United States. The company builds its pipeline through acquisitions and partnerships to expand its neuropsychiatry and pain management franchises.
Themes: ADHD treatment / CNS stimulants, Chronic pain management / opioids, Abuse-deterrent opioid formulations, Opioid-induced constipation, Specialty pharmaceuticals
Fundamentals
- Price$27.11 as of 2026-08-21 close
- Market cap$883M as of 2026-08-21
- 1-year return-31.4% 2025-08-21 close $39.52 → 2026-08-21 close $27.11
- P/E19.04 as of 2026-08-24
- Net margin+5.9% as of 2026-08-24
- Gross margin+60.0% as of 2026-08-24
- ROE+16.0% as of 2026-08-24
- Debt / equity3.89 as of 2026-08-24
- Revenue growth (YoY)+14.3% as of 2026-08-24
- Revenue CAGR (3y)+18.9% SEC XBRL
- Beta0.74 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How COLL compares in its sector
- price-to-earnings ratiomiddle range 203 covered Health Care peers, as of 2026-08-24
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating margintop 25% 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How COLLEGIUM PHARMACEUTICAL INC looks technically
COLLEGIUM PHARMACEUTICAL INC (COLL) is trading 30.4% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 89 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 28, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 32, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 8 trading days ago. It is 46.6% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 30.4% below its 200-day average, the long-term trend line — a long-term downtrend | -30.4% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $33.63 | $33.63 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $38.94 | $38.94 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 9 calendar days ago — the swings before that are what the structure reading is measured on | 9 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 34. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible downward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 89 trading days ago — a "death cross", a bearish long-term signal | 89 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 28, with sellers in control | 27.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 32, neither overbought (above 70) nor oversold (below 30) | 32.2 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($25.47 to $36.42) — its "stochastic" reading is 15 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 15.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 30 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $50.79 | $50.79 |
|---|---|---|
| From the 52-week high | it is 46.6% below its 52-week high (its highest price of the past year) | -46.6% |
| Above the 52-week low | it is 6.4% above its 52-week low (its lowest price of the past year) | +6.4% |
| Below the 52-week high | it is 46.6% below its highest point of the past year | 46.6% |
| Since a 20-day breakout | it made a new 20-day low about 8 trading days ago | 8 sessions |
| Since a 55-day breakout | it made a new 55-day low about 8 trading days ago | 8 sessions |
| All-time high | its highest closing price on record is $50.79 (set on 2025-12-29) | $50.79 |
| Given back of the 52-week move | over the past year its closes ranged ($25.70 to $49.84), and it has recovered only a small part of its fall from last year’s high — 6% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $40.62 to $41.39. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 5.8% |
| From the all-time high | it is 46.6% below its all-time high | -46.6% |
| Nearest price level | it is trading 4.1% below a resistance level at $28.23 — a price it turned at three times since 2025-01-03, most recently on 2025-05-23. Since 2024-08-21 it has 0 such levels below the current price and 14 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +4.1% |
| All-time low | its lowest closing price on record is $7.37 (set on 2017-05-09) | $7.37 |
| Above the all-time low | it is 267.8% above its all-time low | +267.8% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 99% of the past ~6 months) | 99th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.54 between its high and its low — about 5.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.54 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $23.01 and $38.98 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $23.01 – $31.00 – $38.98 |
| Typical daily range (% of price) | its price moves about 5.7% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.7% |
| Stretch from the 200-day average | it is trading 7.7 daily ranges below its 200-day average price (30.4% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 7.7 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.16× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.5% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.5% |
|---|---|---|
| Open gap | it gapped 7.9% above the previous close 6 sessions ago and has not traded back through the level it left behind at 25.7 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +7.9% |
| Gap filled | a 4.0% gap down opened on 2026-06-17 has been "filled" 45 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 45 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -5.67% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 26.7 percentage points (the stock lost 24.4% while the market gained 2.3%) | -26.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 24.3 percentage points (the stock lost 21.2% while the market gained 3.1%) | -24.3% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 50.8 percentage points (the stock lost 39.8% while the market gained 11.1%) | -50.8% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 51.9 percentage points (the stock lost 31.4% while the market gained 20.5%) | -51.9% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: a strong downtrend, with sellers in control, a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 23% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thin, spanning 1.4% of the share price, which is taken to mean a barrier that gives way easily. | -23.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 25% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $36.22 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | -25.2% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $27.87 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | -2.7% |
Price levels it has turned at before
COLL last closed at $27.11 on 2026-08-21. Since 2024-08-21 it has turned at 0 prices below its last close and 14 above; the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $28.23 | Resistance | 4.1% above the last close | turned there three times · 2025-01-03 to 2025-05-23 |
| $29.19 | Resistance | 7.7% above the last close | turned there four times · 2024-11-18 to 2025-08-01 |
| $30.47 | Resistance | 12.4% above the last close | turned there six times · 2025-03-11 to 2026-06-03 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $34.00.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $28.10 and $31.05 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close below $25.47.
This reading has stood for 3 trading days, since 2026-08-19.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · lagging the market · Stretched far below its 200-day average (6+ daily ranges) · At the bottom of its 14-day range (stochastic below 20) · Under water since its last earnings report (below the anchored VWAP) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.80 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
- Mean price target$51.20 range $43.00 – $60.00; median $51.00
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for COLL
- Consensus EPS estimate$1.87 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Generic competition and loss of exclusivity: Third-party generic Nucynta IR launched January 2026; authorized generic versions of Nucynta IR (February 2026) and Nucynta ER (March 2026) launched by Hikma, significantly reducing revenues from these legacy products which are core to the portfolio.","Opioid regulatory and market scrutiny: All pain management products face ongoing regulatory pressure, prescriber hesitancy, and reimbursement challenges due to opioid crisis concerns; potential further restrictions could impair commercialization and pricing.","Acquisition integration and large cash outlays: Pending $650 million Azstarys acquisition plus prior acquisitions (Ironshore, BDSI) create execution risk, integration costs, and balance-sheet pressure that could constrain financial flexibility and profitability."]
What changed in the latest 10-Q
AI-assisted comparison of COLL's 10-Q filed 2026-05-07 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Added disclosure of Nucynta ER Authorized Generic (AG) and Nucynta IR AG as commercialized products in the newer filing (filed 2026-05-07)
- Added detail that Jornay PM contains 'a Schedule II methylphenidate' in the newer filing (filed 2026-05-07)
- Added disclosure of January 2026 generic approval: 'In January 2026, a generic version of Nucynta IR 50mg, 75mg, and 100mg tablets was approved under an abbreviated New Drug Application (ANDA) filed by a third-party with the FDA which carves out pediatric use from its label' (filed 2026-05-07)
- Added disclosure of authorized generic agreement with Hikma: 'We have entered into an authorized generic agreement with Hikma Pharmaceuticals USA Inc. (Hikma), pursuant to which we granted Hikma rights relating to an authorized generic version of the Nucynta Products in the United States. Hikma launched a generic version of Nucynta IR on February 25, 2026 and a generic version of Nucynta ER on March 11, 2026' (filed 2026-05-07)
- Added disclosure of Azstarys Acquisition: detailed paragraph describing March 19, 2026 Equity Purchase Agreement with Corium for $650 million upfront plus up to $135 million in potential milestone payments (filed 2026-05-07)
- Added detailed financial results table for three months ended March 31, 2026 vs 2025 in the newer filing (filed 2026-05-07)
- Removed:
- Removed reference to 'a Schedule II opioid' descriptor for Xtampza ER in overview (the older filing described it as 'an abuse-deterrent, oral formulation of oxycodone' without the Schedule II designation in that location)
- Removed 'extended-release (ER) and immediate-release (IR) oral formulations' language and replaced with more general references in product descriptions (filed 2025-11-06)
- Removed detailed comparison of three months ended September 30, 2025 vs 2024 financial results and product revenue analysis that appeared in the older filing (filed 2025-11-06)
- Removed nine months ended September 30 financial data table that was in older filing (filed 2025-11-06)
- Reworded:
- Changed mission statement from 'We are building' to 'Our mission is to build' (filed 2026-05-07)
- Reordered treatment areas in overview from 'moderate to severe pain and attention deficit hyperactivity disorder (ADHD)' to 'attention deficit hyperactivity disorder (ADHD) and moderate to severe pain' (filed 2026-05-07)
- Changed Xtampza ER description from 'an abuse-deterrent, oral formulation of oxycodone' to 'an abuse-deterrent, extended-release, oral formulation of oxycodone' (filed 2026-05-07)
- Changed Nucynta Products description from 'extended-release (ER) and immediate-release (IR) formulations of tapentadol. Nucynta ER is indicated' to 'extended-release (ER) and immediate-release (IR) oral formulations of tapentadol, a Schedule II opioid. In November 2008, the FDA approved Nucynta ER and Nucynta IR. Nucynta ER is indicated' (filed 2026-05-07)
- Removed reference to 'New Patient Population exclusivity in pediatrics for Nucynta IR' and changed to 'New Patient Population exclusivity for Nucynta IR in pediatric patients' (filed 2026-05-07)
- Changed Symproic description from 'Symproic was approved' to 'Symproic, an oral formulation of naldemedine, was approved' (filed 2026-05-07)
- Notes:
- Older filing covers nine months ended September 30, 2025 and three months ended September 30, 2025; newer filing covers three months ended March 31, 2026. The comparison is between different fiscal periods, making some changes reflect period-specific disclosures rather than policy changes.
- The newer filing's financial results table is truncated at 'Product revenues, net' line item in the source provided, so the full detailed comparison of results is not fully assessable.
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
- Last 180 days0 buys · 4 sells ($628580) — 3 selling insiders
Most recent open-market transaction: 2026-05-18. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about COLL's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding COLL as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 8,215,840
- Reported value $271,697,841
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
COLL had 5,080,634 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
COLL had 15.6% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 17.35 days to cover at the same settlement.
- Reported short interest (shares) 5,080,634
- Short interest (% of shares outstanding) 15.6%
- Prior settlement (shares) 5,233,514
- Reported change -2.92%
- Days to cover (reported) 17.35
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Purdue Pharma (oxycodone/opioid pain management)
- Janssen Pharmaceuticals / Johnson & Johnson (pain opioids)
- Endo Pharmaceuticals (pain management)
- Noven Pharmaceuticals (pain/transdermal delivery)
- Shionogi (pain/Nucynta originator)
- Naurex / Pfizer (ADHD stimulants)
- Adlon Therapeutics / Purdue (ADHD)
- Adzenys XR-ODT / Neos Therapeutics (ADHD)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Frequently asked questions
What does COLLEGIUM PHARMACEUTICAL INC (COLL) do?
Collegium Pharmaceutical is a diversified biopharmaceutical company that develops, licenses, and commercializes branded prescription medicines for ADHD and moderate to severe pain management. The company's portfolio includes Jornay PM (evening-dosed ADHD stimulant), Belbuca (buprenorphine-based pain treatment), Xtampza ER (abuse-deterrent oxycodone), the Nucynta products (tapentadol formulations for pain), and Symproic (opioid-induced constipation treatment), all marketed in the United States.
What sector is COLLEGIUM PHARMACEUTICAL INC (COLL) in?
COLLEGIUM PHARMACEUTICAL INC (COLL) is classified in the Health Care sector. Its industry is Specialty pain management and ADHD pharmaceuticals. It trades on NASDAQ.
Who are COLLEGIUM PHARMACEUTICAL INC's (COLL) competitors?
Notable peers of COLLEGIUM PHARMACEUTICAL INC (COLL) include Purdue Pharma (oxycodone/opioid pain management), Janssen Pharmaceuticals / Johnson & Johnson (pain opioids), Endo Pharmaceuticals (pain management), Noven Pharmaceuticals (pain/transdermal delivery) and Shionogi (pain/Nucynta originator). This peer set is informational only — not financial advice.
Is COLLEGIUM PHARMACEUTICAL INC (COLL) overbought or oversold right now?
COLLEGIUM PHARMACEUTICAL INC (COLL) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 32, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on COLL come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.